Intraday Trading Highlights
On 3 Feb 2026, Aurobindo Pharma Ltd. opened with a notable gap-up of 6.12%, signalling strong demand from the outset. The stock maintained its upward trajectory throughout the session, touching a day’s high of Rs 1,247.05 before closing with a gain of 5.05%. This intraday performance was significantly ahead of the Pharmaceuticals & Biotechnology sector, which rose by 2.54%, and the Sensex, which ended the day down by 2.76% at 83,920.05 points.
The stock’s closing price was just 2.82% shy of its 52-week high of Rs 1,278, underscoring its proximity to recent peak levels. This marks the second consecutive day of gains, with Aurobindo Pharma delivering a cumulative return of 6.34% over this period.
Technical Positioning and Moving Averages
Aurobindo Pharma’s price action remains technically strong, trading above all key moving averages including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This alignment suggests sustained positive momentum and a bullish trend across multiple timeframes. The stock’s Mojo Score currently stands at 52.0, with a Mojo Grade of Hold, reflecting a recent downgrade from Buy on 1 Dec 2025. Despite this, the stock’s market cap grade remains modest at 2, indicating room for further market recognition.
Our latest monthly pick, this Small Cap from Oil Exploration/Refineries, is showing strong performance since announcement! See why our Investment Committee chose it after screening 50+ candidates.
- - Investment Committee approved
- - 50+ candidates screened
- - Strong post-announcement performance
Comparative Performance Analysis
Over various time horizons, Aurobindo Pharma has consistently outperformed the Sensex benchmark. Its one-day gain of 5.25% notably eclipsed the Sensex’s 2.68% rise on the same day. Over the past week, the stock surged 9.44% compared to the Sensex’s 2.44%, while its one-month return of 1.89% contrasted with the Sensex’s decline of 2.23%. The three-month performance further highlights the stock’s resilience, with a 6.80% gain against a marginal Sensex loss of 0.15%.
Year-to-date, Aurobindo Pharma has advanced 4.71%, outperforming the Sensex which has fallen 1.61%. Over longer periods, the stock’s returns remain impressive, with a one-year gain of 9.75% versus the Sensex’s 8.64%, and a three-year return of 206.21% compared to the Sensex’s 37.82%. However, over five and ten years, the stock’s growth of 34.43% and 60.45% respectively trails the Sensex’s 66.85% and 246.16%, reflecting differing sectoral dynamics and market cycles.
Sector and Market Context
The Pharmaceuticals & Biotechnology sector, to which Aurobindo Pharma belongs, gained 2.54% on the day, supported by selective buying interest. In contrast, the broader market experienced a pullback after a strong gap-up opening, with the Sensex retreating by 1,403.15 points from its intraday high. The Sensex remains 2.67% below its 52-week peak of 86,159.02 points and is currently trading below its 50-day moving average, although the 50DMA itself remains above the 200DMA, indicating a longer-term positive trend.
Market leadership was concentrated among mega-cap stocks, which helped limit broader losses. Aurobindo Pharma’s outperformance amid this environment highlights its relative strength within the mid-cap pharmaceutical space.
Holding Aurobindo Pharma Ltd. from Pharmaceuticals & Biotechnology? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Summary of Trading Action
Aurobindo Pharma’s strong intraday performance on 3 Feb 2026 was characterised by a decisive gap-up opening and sustained buying interest throughout the session. The stock’s ability to trade above all major moving averages and close near its intraday peak reflects robust technical positioning. Its outperformance relative to both the sector and the Sensex amidst a broadly weaker market underscores its current market strength.
While the Mojo Grade was downgraded to Hold from Buy on 1 Dec 2025, the stock’s recent price action suggests that it remains a key player within the Pharmaceuticals & Biotechnology sector. The market cap grade of 2 indicates that the stock is still developing its market presence relative to larger peers.
Investors tracking sectoral trends and technical momentum will note Aurobindo Pharma’s consistent gains over multiple timeframes, particularly its strong short-term returns and proximity to 52-week highs.
Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →
